Effect of tibolone and raloxifene on serum markers of apoptosis in postmenopausal women. (April 2013)

• Record Type: Journal Article
• Authors: Lambrinoudaki, I.; Karaflou, M.; Kaparos, G.; Alexandrou, A.; Creatsa, M.; Aravantinos, L.; Augoulea, A.; Kouskouni, E.
• Is Part Of: Climacteric. Volume 16:Number 2(2013:Apr.)
• Page Start: 258
• Page End: 264
• Publication Date: 2013-04
• Subjects: Menopause -- Periodicals; Menopause -- Hormone therapy -- Periodicals; Menopause -- Periodicals; Estrogen Replacement Therapy -- Periodicals; Gynecology -- Periodicals; Societies, Medical -- Periodicals; 612.665
• DOI: 10.3109/13697137.2012.668251
• Languages: English
• ISSNs: 1369-7137

Abstract

<abstract> <title>ABSTRACT</title> <p> <italic>Objectives</italic> To investigate the effect of tibolone and raloxifene on the serum apoptotic markers soluble Fas (sFas), soluble Fas ligand (sFasL) and cytochrome-c (cyt-c) in postmenopausal women.</p> <p> <italic>Methods</italic> A total of 89 healthy postmenopausal women, attending the University Menopause Clinic, were randomly allocated to tibolone (<italic>n</italic> =30), raloxifene (<italic>n</italic> =29) or no treatment (<italic>n</italic> =30). Serum apoptotic markers sFas, sFasL and cyt-c were measured at baseline and at 6 months.</p> <p> <italic>Results</italic> Serum sFasL decreased significantly in women receiving tibolone (baseline: 53.8±28.3 pg/ml, 6 months: 40.45±19.2 pg/ml, <italic>p</italic> =0.001), whilst sFas levels did not significantly change in this group. Serum sFas or sFasL did not change either in the raloxifene group or in the control group. Serum cyt-c concentrations were under the detection limit of the assay in all women assessed.</p> <p> <italic>Conclusions</italic> Tibolone use resulted in a significant decrease in serum sFasL, but not in serum sFas. Raloxifene had no effect on either sFas or sFasL. These results may indicate that tibolone use is associated with a decrease in receptor-mediated apoptosis.</p> </abstract>